According to the data derived from several national and international registries, including SANI(Severe Asthma Network Italy), and considering the strong impact that frequent or regular use oforal corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs formanaging corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should beconsidered a primary outcome in the management of severe asthma. New biologics have clearlydemonstrated that this effect is possible, with concomitant reduction in the rate of exacerbationsand in symptom control. Then, there is no reason for using so frequently oral corticosteroid beforehaving explored all alternatives currently available for a large part of severe asthmatics.
Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI)
Luisa Ricciardi;
2020-01-01
Abstract
According to the data derived from several national and international registries, including SANI(Severe Asthma Network Italy), and considering the strong impact that frequent or regular use oforal corticosteroid has on quality of life (QoL) of severe asthmatics, as well as on the costs formanaging corticosteroid-related diseases, oral corticosteroid sparing up to withdrawal should beconsidered a primary outcome in the management of severe asthma. New biologics have clearlydemonstrated that this effect is possible, with concomitant reduction in the rate of exacerbationsand in symptom control. Then, there is no reason for using so frequently oral corticosteroid beforehaving explored all alternatives currently available for a large part of severe asthmatics.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
